Development and assessment of a novel magnetic nanoparticle antibody-conjugate and aptamer-based assay (MNp-Ab-Ap assay) for the rapid diagnosis of pleural tuberculosis.

Q1 Pharmacology, Toxicology and Pharmaceutics
Pratibha Sharma, Rakesh Kumar Gupta, Simran Aittan, Divya Anthwal, Manisha Dass, Rakesh Yadav, Ashish Behera, Abhijeet Dhiman, Sahajal Dhooria, Sunil Sethi, Ritu Singhal, Puneet Arora, Ashutosh Nath Aggarwal, Tarun Kumar Sharma, Sagarika Haldar
{"title":"Development and assessment of a novel magnetic nanoparticle antibody-conjugate and aptamer-based assay (MNp-Ab-Ap assay) for the rapid diagnosis of pleural tuberculosis.","authors":"Pratibha Sharma, Rakesh Kumar Gupta, Simran Aittan, Divya Anthwal, Manisha Dass, Rakesh Yadav, Ashish Behera, Abhijeet Dhiman, Sahajal Dhooria, Sunil Sethi, Ritu Singhal, Puneet Arora, Ashutosh Nath Aggarwal, Tarun Kumar Sharma, Sagarika Haldar","doi":"10.7150/ntno.95332","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Pleural tuberculosis (pTB) is a diagnostic challenge because of its non-specific clinical features, lack of accurate diagnostic tools and paucibacillary nature of the disease. <b>Methods:</b> We, here describe the development of a novel magnetic nanoparticle antibody-conjugate and aptamer-based assay (MNp-Ab-Ap assay) targeting 4 different <i>Mycobacterium tuberculosis</i> (<i>M</i>. <i>tb.</i>) antigens (GlcB, MPT51, MPT64 and CFP-10) for pTB diagnosis. The MNp-Ab-Ap assay was developed by conjugating polyclonal antibodies on the surface of magnetic nanoparticles (MNPs) by using EDC-NHS chemistry. These conjugated MNPs were used to capture <i>M. tb.</i> antigens present in the pleural fluid samples. The resulting antigen-antibody complex was detected by antigen-specific 5'-biotinylated aptamers. All assays were standardized using samples of the 'Development set' (n=17) and evaluated in the 'Validation set' (n=114) in a blinded manner. Patient categorization was done using a 'Composite Reference Standard'. Assay cut-offs were determined from the 'Development set' (n=17; 'Definite & Probable' pTB; n=9 and 'Non-TB'; n=8) by calculating mean+3SD of OD<sub>450</sub> values of the 'Non-TB' group and applied to 'Validation set' (n=114; 'Definite' pTB; n=8, 'Probable' pTB; n=34, 'Possible' pTB; n=28 and 'Non-TB'; n=44). <b>Results:</b> Out of the 4 assays, MPT51-based MNp-Ab-Ap assay performed the best with 66.6% (95%CI;50.4-80.4) sensitivity and 95.4% (95%CI;85.1-99.4) specificity in the combined 'Definite and Probable' pTB group. Xpert MTB/RIF assay detected only six samples in the 'Validation set'. Binary logistic regression analysis indicated that MPT51-based MNp-Ab-Ap assay provided an incremental advantage over the existing diagnostic algorithm for pTB. <b>Conclusions:</b> We conclude that MPT51-based MNp-Ab-Ap assay is a novel technique that can pave the way towards rapid and accurate diagnosis of pTB.</p>","PeriodicalId":36934,"journal":{"name":"Nanotheranostics","volume":"9 1","pages":"20-30"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11667566/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nanotheranostics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7150/ntno.95332","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Pleural tuberculosis (pTB) is a diagnostic challenge because of its non-specific clinical features, lack of accurate diagnostic tools and paucibacillary nature of the disease. Methods: We, here describe the development of a novel magnetic nanoparticle antibody-conjugate and aptamer-based assay (MNp-Ab-Ap assay) targeting 4 different Mycobacterium tuberculosis (M. tb.) antigens (GlcB, MPT51, MPT64 and CFP-10) for pTB diagnosis. The MNp-Ab-Ap assay was developed by conjugating polyclonal antibodies on the surface of magnetic nanoparticles (MNPs) by using EDC-NHS chemistry. These conjugated MNPs were used to capture M. tb. antigens present in the pleural fluid samples. The resulting antigen-antibody complex was detected by antigen-specific 5'-biotinylated aptamers. All assays were standardized using samples of the 'Development set' (n=17) and evaluated in the 'Validation set' (n=114) in a blinded manner. Patient categorization was done using a 'Composite Reference Standard'. Assay cut-offs were determined from the 'Development set' (n=17; 'Definite & Probable' pTB; n=9 and 'Non-TB'; n=8) by calculating mean+3SD of OD450 values of the 'Non-TB' group and applied to 'Validation set' (n=114; 'Definite' pTB; n=8, 'Probable' pTB; n=34, 'Possible' pTB; n=28 and 'Non-TB'; n=44). Results: Out of the 4 assays, MPT51-based MNp-Ab-Ap assay performed the best with 66.6% (95%CI;50.4-80.4) sensitivity and 95.4% (95%CI;85.1-99.4) specificity in the combined 'Definite and Probable' pTB group. Xpert MTB/RIF assay detected only six samples in the 'Validation set'. Binary logistic regression analysis indicated that MPT51-based MNp-Ab-Ap assay provided an incremental advantage over the existing diagnostic algorithm for pTB. Conclusions: We conclude that MPT51-based MNp-Ab-Ap assay is a novel technique that can pave the way towards rapid and accurate diagnosis of pTB.

开发和评估一种新的基于磁性纳米颗粒抗体偶联和适配体的快速诊断胸膜结核的检测方法(MNp-Ab-Ap检测)。
背景:胸膜结核(pTB)由于其非特异性的临床特征,缺乏准确的诊断工具和疾病的少菌性,是一个诊断挑战。方法:我们在这里描述了一种新的磁性纳米颗粒抗体偶联和适配体为基础的检测方法(MNp-Ab-Ap检测),针对4种不同的结核分枝杆菌(M. tb)抗原(GlcB, MPT51, MPT64和CFP-10)进行pTB诊断。通过EDC-NHS化学将多克隆抗体偶联在磁性纳米颗粒(MNPs)表面,建立MNp-Ab-Ap检测方法。利用这些共轭MNPs捕获结核分枝杆菌。胸膜液样本中有抗原所得抗原-抗体复合物用抗原特异性5′-生物素化适配体检测。使用“开发集”(n=17)的样本对所有分析进行标准化,并在“验证集”(n=114)中进行盲法评估。采用“综合参考标准”对患者进行分类。从“发展集”(n=17;“确定和可能”肺结核;n=9和‘Non-TB’;n=8)通过计算“非tb”组OD450值的平均值+3SD,并应用于“验证集”(n=114;“定”肺结核;n=8, 'Probable' pTB;n=34,“可能”pTB;n=28和‘Non-TB’;n = 44)。结果:在4种检测方法中,基于mpt51的MNp-Ab-Ap检测在“确定和可能”联合pTB组中表现最好,灵敏度为66.6% (95%CI;50.4-80.4),特异性为95.4% (95%CI;85.1-99.4)。Xpert MTB/RIF检测在“验证集”中仅检测到6个样品。二元逻辑回归分析表明,基于mpt51的MNp-Ab-Ap检测比现有的pTB诊断算法具有递增优势。结论:基于mpt51的MNp-Ab-Ap检测是一种新型的pTB快速准确诊断技术。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Nanotheranostics
Nanotheranostics Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
CiteScore
10.40
自引率
0.00%
发文量
37
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信